Starting With Triple Therapy Including Exenatide vs Sequential Add-On for Type 2 Diabetes | Research

The takeaway

Initial triple therapy including the GLP-1 drug exenatide provided superior glycemic and non-glycemic benefits compared to traditional sequential add-on approach in newly diagnosed type 2 diabetes.

Start aggressive
Triple therapy including exenatide from diagnosis outperformed the traditional one-drug-at-a-time approach for diabetes

What the researchers found

Initial triple therapy including exenatide provided superior glycemic control and non-glycemic benefits (weight, blood pressure) compared to sequential add-on therapy in type 2 diabetes.

Why it matters

Delaying effective treatment allows diabetes to progressively damage beta cells. Starting with triple therapy including a GLP-1 drug may preserve beta cell function and achieve better long-term outcomes.

The numbers in context

29 patients received initial triple therapy. Both groups maintained good blood sugar control for 6 years. Specific cIMT and liver fat measurements were compared.

How the study worked

Comparative study of initial triple therapy (including exenatide) versus sequential add-on in patients with type 2 diabetes. Assessed HbA1c, body weight, blood pressure, and metabolic parameters.

Who was studied

Patients with new-onset type 2 diabetes in the EDICT study

What this study cannot tell us

Study design and duration vary. Triple therapy is more complex and expensive. Patient adherence to three drugs from the start may be challenging. Long-term outcomes need confirmation.

How to read the evidence

Moderate evidence: comparative study showing triple therapy superiority, though long-term outcomes need confirmation.

When this study was published

Published in 2025. Supports the emerging paradigm of early aggressive combination therapy for diabetes.

The bigger picture

The diabetes treatment paradigm is shifting from conservative, step-wise escalation to early aggressive combination therapy. Including GLP-1 drugs from the start leverages their multi-organ benefits (glycemic control, weight loss, cardiovascular protection) from day one.

Questions still open

Does early triple therapy prevent long-term beta cell decline better than sequential approach?
Which GLP-1 drug is optimal as a component of initial triple therapy?
Is the added cost of triple therapy offset by better long-term outcomes?

Common questions

Should I start multiple diabetes drugs at once?

This study suggests starting with triple therapy including a GLP-1 drug provides better results than adding drugs one at a time. The advantage is faster blood sugar control, weight loss, and potentially better preservation of your insulin-producing cells.

Why not just start with one drug first?

Traditional step-wise treatment means your blood sugar stays elevated for months while drugs are added sequentially. During this time, high blood sugar continues to damage beta cells. Starting aggressively may prevent this progressive damage.

Read the original research

Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study.

BMJ open diabetes research & care, 13(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Abdul-Ghani, Muhammad; Puckett, Curtiss; Abdelgani, Siham; Merovci, Aurora; Lavrynenko, Olga; Adams, John; Triplitt, Curtis; DeFronzo, Ralph A. (2025). Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study.. BMJ open diabetes research & care, 13(2). https://doi.org/10.1136/bmjdrc-2025-004981